Skip to main content
. 2022 Jan 18;12:789319. doi: 10.3389/fphar.2021.789319

TABLE 1.

Characteristics of included trials.

Trial Study design Recruitment period Median follow-up (month) Interventions Sample size
COU-AA-301 Phase 3, multicenter, double-blind, RCT May 2008 to Jul 2009 20.2 Abiraterone + prednisone vs. placebo + prednisone 797 vs. 398
Sun et al. (2016) Phase 3, multicenter, double-blind, RCT Aug 2012 to Nov 2013 12.9 Abiraterone + prednisone vs. placebo + prednisone 143 vs. 71
AFFIRM Phase 3, multicenter, double-blind, RCT Sep 2009 to Nov 2010 14.4 Enzalutamide vs. placebo 800 vs. 399
TROPIC Phase 3, multicenter, open-label, RCT Jan 2007 to Oct 2008 12.8 Cabazitaxel + prednisone vs. mitoxantrone + prednisone 378 vs. 377
ALSYMPCA Phase 3, multicenter, open-label, RCT Jun 2008 to Feb 2011 NA Radium-223 vs. placebo 325 a vs. 174 a

Abbreviations: RCT, randomized controlled trial; NA, not available.

a

Data of patients with previous docetaxel use.